Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

70.18 USD +0.42 (+0.60%)
Official Closing Price Updated: 7:21 PM EST, Mar 3, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Axsome Thera

< Previous 1 2 3 4 5 6 7 Next >
Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate
From GlobeNewswire News Releases
Thinking about buying stock in Advanced Micro Devices, Axsome Therapeutics, FuelCell Energy, Microsoft, or Nio?
InvestorsObserver issues critical PriceWatch Alerts for AMD, AXSM, FCEL, MSFT, and NIO. 
From PR Newswire
Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response
From GlobeNewswire News Releases
Axsome Therapeutics Announces Closing of $200 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From GlobeNewswire News Releases
Thinking about trading options or stock in Apple, Axsome Therapeutics, Deere & Co, Johnson & Johnson, or Eli Lilly?
InvestorsObserver issues critical PriceWatch Alerts for AAPL, AXSM, DE, JNJ, and LLY. 
From PR Newswire
Axsome Therapeutics Announces Pricing of Public Offering of $174 Million of Shares of Common Stock
From GlobeNewswire News Releases
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
Drug Delivery Across Blood Brain Barrier Market Worth $4.6 Billion By 2026
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Drug Delivery Across Blood Brain Barrier Market Worth $4.6 Billion by 2026
Financialnewsmedia.com News Commentary 
From PR Newswire
Axsome Therapeutics Added to NASDAQ Biotechnology Index
From GlobeNewswire News Releases
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder
From GlobeNewswire News Releases
Biotechs Move Forward Developing Latest Targeted Therapies for Acute Myeloid Leukemia
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Biotechs Move Forward Developing Latest Targeted Therapies for Acute Myeloid Leukemia
Financialnewsmedia.com News Commentary 
From PR Newswire
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy
From GlobeNewswire News Releases
Axsome Therapeutics to Host Investor R&D Call with Key Opinion Leaders Focusing on AXS-07 and the Unmet Needs in the Acute Treatment of Migraine
From GlobeNewswire News Releases
Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Axsome Therapeutics to Report Third Quarter 2019 Financial Results on November 7, 2019
From GlobeNewswire News Releases
Axsome Therapeutics Announces Results of MINDSET Physician Survey Affirming Unmet Need and Favorable Profile of AXS-07 in the Acute Treatment of Migraine
From GlobeNewswire News Releases
Axsome Therapeutics Announces Continued Progress in Clinical Development of AXS-07 for the Acute Treatment of Migraine
From GlobeNewswire News Releases
Axsome Therapeutics Completes Patient Enrollment in the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy
From GlobeNewswire News Releases
Axsome Therapeutics Announces Completion of Patient Enrollment in the GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
From GlobeNewswire News Releases
Axsome Therapeutics to Provide Update on Continued Progress at the 2019 Cantor Global Healthcare Conference
From GlobeNewswire News Releases
NetworkNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Making Significant Advances in Drug Delivery
From InvestorBrandNetwork
Axsome Therapeutics Presents Positive AXS-07 Phase 1 Trial Results at the 19th Congress of the International Headache Society
From GlobeNewswire News Releases
Innovative Drug-Delivery Systems Benefit Patients and Businesses
From InvestorBrandNetwork
Innovative Drug-Delivery Systems Benefit Patients and Businesses
NetworkNewsWire Editorial Coverage 
From PR Newswire
Axsome Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
From GlobeNewswire News Releases
Axsome Therapeutics Appoints David Marek as Chief Commercial Officer
From GlobeNewswire News Releases
Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Axsome Therapeutics To Report Second Quarter 2019 Financial Results On August 8, 2019
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.